APA Alıntı

Rottenburger, C., Nicolas, G. P., McDougall, L., Kaul, F., Cachovan, M., Vija, A. H., . . . Wild, D. (2020). Cholecystokinin 2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study. J Nucl Med.

Chicago Stili Alıntı

Rottenburger, Christof, et al. "Cholecystokinin 2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study." J Nucl Med 2020.

MLA Alıntı

Rottenburger, Christof, et al. "Cholecystokinin 2 Receptor Agonist (177)Lu-PP-F11N for Radionuclide Therapy of Medullary Thyroid Carcinoma: Results of the Lumed Phase 0a Study." J Nucl Med 2020.